Outlook Therapeutics (OTLK) Return on Capital Employed (2016 - 2026)
Outlook Therapeutics (OTLK) reported Return on Capital Employed of 321.89% for Q1 2026, down 80525.0% year-over-year from N/an in Q1 2025, and up 67.36% quarter-over-quarter from 192.33% in Q4 2025.
Outlook Therapeutics (OTLK) Return on Capital Employed (2016 - 2026) Analysis & Trends
Outlook Therapeutics (OTLK) has 11 years of Return on Capital Employed data on file, last reported at 321.89% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 321.89%, down 80525.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 321.89% (down 80525.0% YoY), and the FY2025 annual result was 303.3%, down 29464.0% from the prior year.
- Return on Capital Employed advanced to 321.89% in Q1 2026 per OTLK's latest filing, from 192.33% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 7870.81% in Q2 2023 and troughed at 583.31% in Q2 2024.
- A 5-year average of 690.09% and a median of 264.79% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed surged 805094 bps in 2023, then plunged 845412 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 214.93% in 2022, then surged by 217 bps to 251.69% in 2023, then soared by 30 bps to 327.72% in 2024, then slumped by 41 bps to 192.33% in 2025, then surged by 67 bps to 321.89% in 2026.
- Business Quant data shows OTLK's Return on Capital Employed at 321.89% in Q1 2026, 192.33% in Q4 2025, and 264.79% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | Outlook Therapeutics | 51.13 Mn | 43.39 Mn | -21,888.00 | 321.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 321.89% |
| Dec 31, 2025 | 192.33% |
| Sep 30, 2025 | 264.79% |
| Jun 30, 2025 | 675.22% |
| Mar 31, 2025 | 1,127.14% |
| Dec 31, 2024 | 327.72% |
| Sep 30, 2024 | 1,560.02% |
| Jun 30, 2024 | -583.31% |
| Mar 31, 2024 | 436.21% |
| Dec 31, 2023 | 251.69% |
| Sep 30, 2023 | 635.61% |
| Jun 30, 2023 | 7,870.81% |
| Mar 31, 2023 | -361.05% |
| Dec 31, 2022 | -214.93% |
| Sep 30, 2022 | -456.11% |
| Jun 30, 2022 | -180.13% |
| Mar 31, 2022 | -136.39% |
| Dec 31, 2021 | -164.58% |
| Sep 30, 2021 | -245.21% |
| Jun 30, 2021 | -249.53% |